Life Science Leader and Industry Standard Research conduct an annual Contract Research Organization Quality Benchmarking online survey. Based on this research, top CRO leaders are rewarded for their service. View the 2019 results now.

Only 15% of oncology drugs that get started in clinical trials reach phase III studies, and the likelihood of approval for any new anticancer drug entering clinical trials is just over 5%. But why is the success rate so dismal? In this eBook, we’ll review the common reasons that these trials fail (and how you can take steps to ensure success).

See how the top clinical research organizations compare. Worldwide Clinical Trials is proud to be listed as a top quality performer in these areas of Phase I CRO services: Overall CRO Services, Accessibility, Services, and Customer Loyalty.

Do you have all the tools to be successful in your patient recruitment and retention efforts? Watch our latest webinar to arm yourself with the best tools from award-winning CRO, Worldwide Clinical Trials.

We’re in a transformative period for Real-World Evidence in which increased stakeholder acceptance is being achieved through advances in technology, improved methodology, regulatory endorsement, and an overall recognition of the importance of the real-world in drug development and commercialization. In this eBook, Worldwide unlocks for trends to consider before you take the first step.

There are unique challenges you may face during early phase oncology research. Our latest infographic details 6 ways Worldwide can help you overcome any unexpected developments.